A new scientific statement released by the Endocrine Society today exposes possible research directions related to the pathogenesis of type 1 diabetes (T1D) that should help in the development of new and better treatment options.

Type 1 diabetes is a chronic disease where the body’s immune system attacks and destroys insulin-producing cells in pancreatic islet. Type 1 diabetes requires a lifelong insulin administration and can result in complications such as eye, kidney, nerve and heart disease. Type 1 diabetes is usually considered to be a disease of children and adolescents, but now it is believed that T1D is often a beginning in adults and can occur at any age.

Endocrine society develops scientific statements to detect scientific basis of conditions and diseases related to hormones, discusses how this knowledge can be applied in practice, and identify areas that require additional research. The subjects are chosen based on their emerging scientific influence. The scientific statement is developed by a task force of experts appointed by the Endocrine Society, with internal reviews by the concerned social committees and expert external critics before the open comment period for all members of the society.

The Endocrine Society chose type 1 diabetes for a scientific statement as research related to T1D is rapidly expanding, and the area is designed for new advances. The hope is that scientific statements will provide scientists, physicians and funding agencies a guide for research areas that seem particularly promising. ,

Alvin c. Power, MD, Vendorbult University Medical Center, Tenne., Member of Writing Group

According to the International Diabetes Federation, in 2024, 9 million people had type 1 diabetes, with a lot of variation in rates in countries.

The causes and factors leading to type 1 diabetes are unknown. Scientific statement briefly stated research and suggestions for new research in these fields related to T1D: Analysis, inequality, pancreas pathology, assessment of of cell function and mass, immunological biomarkers in peripheral blood, changes in exocrine pancreas, and screening to identify the risk for T1D.

“Data type 1 highlights more research in the need for population-based screening for type 1 diabetes,” Powerrs said. “We hope to address these research gaps and include more comprehensive screening efforts will soon help people identify risk and improve treatment and long -term health results for people. Living with type 1 diabetes,

This statement is based on the updated version of the widely quoted and often modified eisenbarth models, which outlines different stages of progress for type 1 diabetes. The scientific statement proposes that Phase 0 should be added to this model that already included stages 1, 2, and 3, to highlight that there are possibilities of earlier events in the disease that are currently not understood or not being studied.

“We hope that research in these areas with information from the application of emerging technical and analytical devices will create a new understanding of the pathogenesis of type 1 diabetes,” Powerrs concluded.

Other statements are Aaron Michelle at the University of Colorado School of Medicine in Kolo, Writer Denver, Kolo; Gainesville, Florida University’s Tod Bricco in Fla; Carmella Evans-Molina of Indiana University School of Medicine and Rowdebash VA Medical Center at Industries, Industries; Miami University, Miami, Fla; And Sara Richardson of Exeter Medical School University in UK Exeter

The statement, “Type 1 Diabetes: The Nay Endocrine Society was published online in the Society’s Journal, Journal of Clinical Endocrinology and Metabolism.